替莫唑胺治疗顺铂难治性生殖细胞肿瘤患者的II期试验。
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
作者信息
Varuni Kondagunta G, Bacik Jennifer, Schwartz Lawrence, Sheinfeld Joel, Bajorin Dean, Vuky Jacqueline, Marion Stephanie, Mazumdar Madhu, Bosl George J, Motzer Robert J
机构信息
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
出版信息
Invest New Drugs. 2004 Apr;22(2):177-9. doi: 10.1023/B:DRUG.0000011794.21608.59.
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
14例顺铂难治性生殖细胞肿瘤（GCT）患者在一项II期试验中接受了替莫唑胺治疗。替莫唑胺在第1 - 5天以150 mg/m²/天的剂量口服给药。周期长度为28天。没有患者出现3级或4级毒性，14例可评估患者中无一例获得完全缓解或部分缓解。替莫唑胺对顺铂难治性GCT患者的治疗无效。
Zotero 插件